Physician profile
David Mangels
NPI 1528057437
$1,686.50
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $123 · 2021: $393 · 2022: $621 · 2023: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $165.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $758.42 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $212.62 | 2019-2023 | Entyvio |
| Gilead Sciences, INC. | $157.59 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $78.40 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.08 | 2019-2022 | |
| Pfizer INC. | $69.79 | 2019-2022 | |
| Janssen Biotech, INC. | $59.80 | 2019-2023 | Simponi, Simponi Aria, Stelara |
| Daiichi Sankyo INC. | $58.65 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $48.73 | 2019-2021 | |
| Celgene Corporation | $38.72 | 2021-2023 | Zeposia |
| Ucb, INC. | $35.05 | 2019 | |
| Ironwood Pharmaceuticals, INC | $33.36 | 2020-2022 | |
| Shionogi INC | $15.88 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.25 | 2022 | |
| Allergan, INC. | $13.85 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $13.25 | 2023 | Ocaliva |
| Micro-Tech Endoscopy USA, INC. | $5.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mangels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.